- Home
- WNEB vs ENGN Comparison
WNEB vs ENGN Comparison
Compare WNEB & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNEB
- ENGN
- Stock Information
- Founded
- WNEB 1853
- ENGN 1999
- Country
- WNEB United States
- ENGN Canada
- Employees
- WNEB N/A
- ENGN N/A
- Industry
- WNEB Savings Institutions
- ENGN
- Sector
- WNEB Finance
- ENGN
- Exchange
- WNEB Nasdaq
- ENGN Nasdaq
- Market Cap
- WNEB 195.7M
- ENGN 204.3M
- IPO Year
- WNEB N/A
- ENGN N/A
- Fundamental
- Price
- WNEB $8.67
- ENGN $3.15
- Analyst Decision
- WNEB Buy
- ENGN Buy
- Analyst Count
- WNEB 3
- ENGN 7
- Target Price
- WNEB $9.75
- ENGN $23.29
- AVG Volume (30 Days)
- WNEB 71.5K
- ENGN 74.0K
- Earning Date
- WNEB 07-22-2025
- ENGN 06-12-2025
- Dividend Yield
- WNEB 3.27%
- ENGN N/A
- EPS Growth
- WNEB N/A
- ENGN N/A
- EPS
- WNEB 0.53
- ENGN N/A
- Revenue
- WNEB $72,966,000.00
- ENGN N/A
- Revenue This Year
- WNEB N/A
- ENGN N/A
- Revenue Next Year
- WNEB $7.94
- ENGN N/A
- P/E Ratio
- WNEB $16.23
- ENGN N/A
- Revenue Growth
- WNEB N/A
- ENGN N/A
- 52 Week Low
- WNEB $6.10
- ENGN $2.65
- 52 Week High
- WNEB $10.08
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- WNEB 33.74
- ENGN 37.77
- Support Level
- WNEB $9.28
- ENGN $3.17
- Resistance Level
- WNEB $9.59
- ENGN $3.44
- Average True Range (ATR)
- WNEB 0.21
- ENGN 0.43
- MACD
- WNEB -0.09
- ENGN -0.04
- Stochastic Oscillator
- WNEB 13.62
- ENGN 16.67
About WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.